

Special Issue

MicroRNAs Applications in Cancer, Therapeutics and Related Toxicities

Message from the Guest Editor

Knowledge about microRNAs (miRNAs) has dramatically expanded during the last decade, showing their important role in many diseases and cancer, as well as in the response to therapeutic approaches. Therefore, specific signatures of aberrantly expressed miRNAs harbor diagnostic, prognostic, and therapeutic implications. Changes in miRNA expression occur in response to environmental stimuli and play an important role in the regulation of cancer development and aggressiveness, immune response, and specific treatment efficacy. Currently, there is a critical need to discover biomarkers for risk prediction and early diagnosis of cancer, to monitor progression and to predict clinical outcome, and miRNAs are strong candidates for all these. This Special Issue intends to present original research and reviews in the field of miRNA application in cancer as targeted biomarkers for prognosis, therapeutic efficacy, and therapeutic related toxicities. It also will include the topic of miRNA application in cancer immunotherapy.

Guest Editor

Dr. Enrique Fuentes-Mattei

Immunotherapy-Radiation Oncology Strategic Initiatives, Radiation Oncology Clinical Research, Division of Radiation Oncology, 1515 Holcombe Blvd., Houston, TX 77030, USA

Deadline for manuscript submissions

closed (25 October 2021)

G C A T
T A C G
G C A T

Genes

an Open Access Journal
by MDPI

Impact Factor 2.8
CiteScore 5.5
Indexed in PubMed



mdpi.com/si/49792

Genes
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
genes@mdpi.com

[mdpi.com/journal/
genes](https://mdpi.com/journal/genes)



G C A T
T A C G
G C A T

Genes

an Open Access Journal
by MDPI

Impact Factor 2.8
CiteScore 5.5
Indexed in PubMed



[mdpi.com/journal/
genes](https://mdpi.com/journal/genes)



About the Journal

Message from the Editor-in-Chief

Genes is central to our understanding of biology, and modern advances such as genomics and genome editing have maintained genetics as a vibrant, diverse and fast-moving field. There is a need for good quality, open access journals in this area, and the *Genes* team aims to provide expert manuscript handling, serious peer review, and rapid publication across the whole discipline of genetics. Starting in 2010, the journal is now well established and recognised. Why not consider *Genes* for your next genetics paper?

Editor-in-Chief

Prof. Dr. Selvarangan Ponnazhagan
Experimental Cancer Therapeutics, The University of Alabama at
Birmingham, 1825 University Blvd., SHEL 814, Birmingham, AL 35294-
2182, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAg, and other databases.

Journal Rank:

JCR - Q2 (Genetics and Heredity) / CiteScore - Q2 (Genetics (clinical))